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Background
Tamoxifen, which interferes with estrogen for receptor 
binding, was the ﬁ  rst successful targeted therapy and has 
been the treatment of choice for estrogen receptor (ER)-
positive breast cancers for more than two decades. 
Unfortunately, resistance occurs in approximately 30% of 
patients and the mechanisms of resistance act directly on 
the ER pathway and/or activate parallel pathways that 
block the anti-proliferative and pro-apoptotic actions of 
tamoxifen [1,2]. For example, increased mitogen-
activated protein kinase (MAPK) and phosphatidyl-
inositol 3-kinase (PI3K) signaling downstream of growth 
factor receptors (for example, ERBB2 and Insulin-like 
growth factor 1 receptor (IGF-1R)) has been implicated 
in a crosstalk with ER and in resistance to endocrine 
therapy [1-3].
Th   e PI3K pathway, a central regulator of diverse normal 
cellular functions, is very often subverted during 
neoplastic transformation and contributes to several 
hallmarks of cancer that result in a competitive advantage 
for cancer cells [4-6]. Not surprisingly, the PI3K cascade 
is an attractive therapeutic target and several inhibitors 
are currently in phase I/II clinical trials. Preclinical 
studies have shown that PI3K inhibition circumvents 
resistance to trastuzumab in ERBB2-positive breast 
cancers and this has led to clinical trials combining anti-
ERBB2 and anti-PI3K therapies [7]. Although PI3K has 
been implicated in resistance to endocrine therapy of ER-
positive tumors, several questions remain unanswered. Is 
PI3K inhibition, alone or in combination with tamoxifen, 
eﬀ  ective in tamoxifen-resistant ER-positive cancer cells? 
Does PI3K inhibition block the emergence of tamoxifen 
resistance? Does a PI3K hyperactivation signature in 
human tumors predict tamoxifen sensitivity? Two recent 
papers now provide some answers to these outstanding 
questions.
The articles
Creighton and colleagues [8] investigated the relationship 
between the PI3K pathway and ER levels and activity 
using breast cancer cell lines and data sets of human 
breast tumors, and they deﬁ  ned proteomic and trans-
criptomic signatures of a hyperactivated PI3K pathway. 
Th  ese signatures negatively correlate with ER levels 
within ER-positive human breast tumors and are asso-
ciated with the luminal B breast cancer subtype, the more 
aggressive subtype of ER-positive tumors. In addition, 
the transcriptomic signature was shown to predict the 
worst prognosis in ER-positive tumors. Treatment with 
the dual PI3K/mammalian target of rapamycin (mTOR) 
inhibitor BEZ235 increased ER expression in a number of 
ER-positive breast cancer cell lines. Interestingly,
treatment of two luminal B ER-positive cell lines 
simultaneously with tamoxifen and BEZ-235 reduced cell 
proliferation more than with either inhibitor alone. Of 
note, luminal A tumors might also beneﬁ  t from PI3K 
inhibition as the luminal A cell lines used by Creighton 
and colleagues [8] and by Miller and colleagues [9] are 
also sensitive to BEZ235.
Whether hyperactivation of the PI3K pathway contri-
butes to tamoxifen resistance after chronic tamoxifen 
treatment was not addressed by this study, but was 
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estrogen-independent breast cancer cell lines from 
estrogen-dependent ER-positive lines by long-term 
estrogen deprivation (LTED). Unbiased phosphoprotein 
microarrays, immunocapture arrays and transcription 
proﬁ  ling revealed an increase in PI3K/mTOR signaling as 
a consequence of higher phosphorylation of the insulin 
receptor and/or IGF-1R in LTED cells compared with 
parental cells. Inhibition of PI3K/mTOR using BEZ235 
[10] reduced cell growth in both parental and LTED cells 
and increased apoptosis in most of them. It remains 
unclear whether LTED cells are more reliant on the PI3K 
pathway for survival than their parental counterparts as 
BEZ235 caused a similar level of apoptosis in the two 
lines. Finally, the authors found that the protein signature 
of activated PI3K signaling predicted disease outcome 
after adjuvant endocrine therapy [9].
The viewpoint
Both studies highlight the role of the PI3K pathway in 
resistance to tamoxifen. Creighton and colleagues [8] 
suggest that this eﬀ  ect is caused by PI3K-mediated down-
regulation of ER. Th  is is also supported by the obser-
vation of Miller and colleagues [9] that PI3K pathway 
activation is inversely correlated with expression of ER in 
64 human ER-positive breast tumors. As two lines 
(MCF7-LTED, HCC1428-LTED) used by Miller and 
colleagues showed a hyperactivated PI3K pathway com-
pared with parental cells, but no decrease in ER expres-
sion, it is conceivable that further mechanisms account 
for PI3K-mediated resistance [9]. Altogether, the two 
studies suggest that targeting PI3K/mTOR and ER should 
be eﬀ  ective in ER-positive tumors and warrant comple-
mentary studies using in vivo models. Indeed, the 
interaction of cancer cells with the stroma might modu-
late estrogen sensitivity and lead to diﬀ  erent mechanisms 
of resistance [2].
Although these studies might suggest that ER-positive 
tumors with a hyperactivated PI3K pathway should 
correlate with poor prognosis, this does not seem to be 
the case, at least for tumors showing activation of the 
PI3K pathway  driven by PIK3CA mutations. Indeed, 
three recent studies reported that mutations of PIK3CA, 
in particular the catalytic domain mutation H1047R, are 
associated with better prognosis in ER-positive breast 
cancers [11-13]. Th   is is surprising given the transforming 
eﬀ  ect  of  PIK3CA mutations in experimental systems. 
One possible explanation for this ‘PIK3CA paradox’ is 
that most experimental models assess eﬀ  ects on primary 
tumor growth and not metastases and long-term 
survival. Alternatively, PIK3CA mutations might only 
moderately activate the pathway and/or constitutive 
activity of mutant PIK3CA may induce negative feedback 
loops that preclude a more pronounced activation of the 
pathway [14]. In fact, several cell lines with PIK3CA 
muta  tions (MCF-7, BT-483, MB-361) [15] were associa-
ted with a low/intermediate PI3K score in the proteomic 
signature of Creighton and colleagues [8]. Th  erefore, 
better experimental models and systems biology-like 
assessment of the PI3K network, including the activities 
of all intermediates of the pathway, associated feedback 
loops and collaborating oncogenic pathways, may be 
needed to solve the ‘PIK3CA paradox’.
In summary, these two studies suggest hyperactivation 
of PI3K as a mechanism of resistance to tamoxifen, which 
may have clinical impact. It is reasonable to conclude that 
the combination of endocrine therapy and inhibition of 
PI3K in ER-positive tumors with a hyperactive PI3K 
pathway may be more eﬀ   ective than monotherapy. 
Studies on in vivo breast cancer models with alterations 
in the PI3K pathway should increase our understanding 
of this complex but fascinating signaling network, test 
the validity of this speculation and optimize combination 
therapies. Ultimately, clinical trials testing combinations 
of anti-ER and anti-PI3K therapies may ﬁ  nally lead to 
relapse-free therapy for patients with ER-positive tumors.
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